EC looks for support on central nanotech regulatory drafting framework
This article was originally published in Clinica
The European Commission is calling for responses from interested stakeholders, including the medical technology industry, to the opinion on nanotechnologies that has just been adopted by independent experts at its scientific committee on emerging and newly identified health risks (SCENIHR). Speaking at a conference on nanotechnology held by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on October 27, Didier Bouis, the person in charge of looking into the regulation of all areas of nanotechnology within the European Commission's Directorate General for Enterprise and Industry, explained that the EU is still at very preliminary stages of considering how nanotechnology products, including nanomedicines, should be regulated.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.